Merck’s advanced lung cancer drug gets US drug regulator’s nod
Merck & Co’s combination drug, Keytruda, which treats advanced lung cancer, has been approved by the US drug regulator, the Food and Drug.
Drugs
Health
Pharma
Drugs
Health
Pharma
Summit’s lung cancer drug reduces risk of disease progression by 48%
Summit Therapeutics Inc.’s investigational drug ivonescimab helps lung cancer patients to cut the risk of progression or death from the disease by 48%,.
Drugs
Health
Pharma
US smokers need photo ID to prove new age limit set by the FDA
The US drug regulator raised the age limit of people who want to buy tobacco products by three years to 30, and retailers.
Drugs
Health
Medical
World’s first lung cancer vaccine given to patient in UK as human trials begin
HQ team August 23, 2024: .An mRNA-based lung cancer vaccine is being tested for the first time on patients in the UK. Known.
Drugs
Health
Pharma
Denmark’s Pharmacosmos to buy G1 Therapeutics for $405 million
Danish biotechnology company, Pharmacosmos A/S will buy US-based G1 Therapeutics Inc., for $405 million to expand its global commercial portfolio in haematology.
Drugs
Health
Pharma
FDA rejects Daiichi, Merck, antibody-drug conjugate application
The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat.
Drugs
Health
Pharma
Novartis AG to buy Mariana Oncology for $1 billion to build RLT assets
HQ Team May 2, 2024: Novartis AG will buy a US-based biotechnology company Mariana Oncology to expand its cancer portfolio for $1 billion..
Drugs
Medical
Pharma
UK researchers get $2.1 million to develop lung cancer vaccine
HQ Team March 23, 2024: Researchers in the UK have won a grant of $2.14 million (€1.98 million) from the Cancer Research UK.
Drugs
Health
Pharma
Cancer cases set to rise by 77% to 35 million in 2050: WHO global survey
More than 35 million people may have cancer in 2050 — an increase of 77% from 20 million new cases in 2022, according.
Drugs
Health
Pharma
Bristol Myers acquires Mirati Therapeutics for $5.8 billion
HQ Team October 9, 2023: Bristol Myers Squibb, one of the world’s largest pharmaceutical companies, will acquire Mirati Therapeutics for $5.8 billion through.